Intelgenx (IGXT) Market Cap $32M- FDA Play

Discussion in 'Men's Economics' started by BioSpecialist, May 12, 2013.

  1. BioSpecialist

    BioSpecialist Junior Member


    Intelgenx launched their first drug called Forfivo (antidepressant) in October 2012 this will drive Intelgenx into Profitability this Year because of its very low burn-rate of around $2 Mil a year !

    IGXT Submits NDA for Anti-Migraine Versafilm in March and another 1x NDA filing for Erectile Dysfunction Versafilm and 2x ANDA filings expected in 1H 2013. Two Partnerships for Anti-Migraine and Erectile Dysfunction products also expected in 1H 2013 which means more Cash for Intelgenx .
    Intelgenx has 9 Drugs in late stage which will be all on the Market within 2-3 years .

    IGXT has NO DEBT and Cash untill 2015 means enough to drive this Company into Profitability which is expected for this Year . Current Market Cap of just $33 M is really Brutally Underpriced .

    IGXT share price has the Potential to move into double digits within 2 years ! .GLTA

    Intelgenx (IGXT)

    Market Cap : $32.7 M
    Cash: $3.5 M
    Burn-Rate : $2 M a year

    Price : $0.65

    Shares Out : 50 M ( 27 M shares are held by Insiders & Institutions)

    March 27, 2013 IntelGenx Corp. a Canadian drug delivery company focusing on oral drug delivery, today announced that, together with its co-development partner RedHill Biopharma ("RedHill"), it has submitted a 505(b)(2) New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for the Company's anti-migraine oral film product, a novel oral thin-film formulation based on its proprietary VersaFilm(TM) technology containing Rizatriptan, the active drug in Merck's Maxalt-MLT(R) orally disintegrating tablets.

    "We are very excited that our first FDA-approved product, Forfivo XL(TM), has been launched in the USA in early October by our partner Edgemont Pharmaceuticals. We believe that ForFivo XL(TM), as the only single tablet 450mg bupropion HCl available in the U.S., will be a valuable tool for physicians in their management of patients with major depressive disorders," stated Dr. Horst G. Zerbe, President and CEO of IntelGenx.

    HUGE Prodcut Pipeline

    Upcoming Milestones

    New Presentation March 2013
    IntelGenx Corporate Presentation - March 2013

    Big Buying by Institutions
    IGXT Insider Transactions | INTELGENX TECHNOLOGS Stock - Yahoo! Finance

    Analyst Coverage:

    Aegis Capital --Tgt $2.50

    Cleland shares the names of a handful of small companies that could return tenfold or greater multiples to investors.
    Think Long Term and Win Big with Small Biotechs: Hugh Cleland [CTH, CYNAF] - The Life Sciences Report